Drug facts

What is compounded tirzepatide?

By ·Editor·Reviewed

Quick answer

Tirzepatide prepared by a pharmacy, rather than manufactured and sold as an approved product. It contains the same active molecule as Zepbound and Mounjaro, but it is not FDA-approved, it has no label of its own, and it is not a generic — there is no generic tirzepatide. In FDA’s words, the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.

What compounding means1

FDA’s own definition is short and worth reading as written:

Compounding is generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.

The last four words are the ones that matter for tirzepatide. Compounding exists to make a medicine for one person whose needs an approved product cannot meet. Selling the same preparation to thousands of subscribers is a different activity, and most of what has happened to this market since 2024 follows from that difference.

Not approved, and not a generic2

Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

That is a statement about review, not a verdict on any one vial. It means the three things a label normally guarantees — a reviewed dose schedule, reviewed manufacturing and trial evidence for that exact product — do not come with a compounded preparation. A generic would bring them: FDA approves a generic by requiring it to match the brand, and states plainly that a compounded drug is not that. Nobody sells an approved generic tirzepatide.

On the label — Mounjaro / Zepbound

Two approved products, Zepbound and Mounjaro, both from Eli Lilly — each with a label, reviewed manufacturing and trials of its own.

In a compounded vial

The same active molecule, prepared by a pharmacy you may never have heard of, with a strength, a beyond-use date and sometimes extra ingredients that the pharmacy chose.

The item-by-item comparison is in compounded tirzepatide vs Zepbound, and, for readers with type 2 diabetes, compounded tirzepatide vs Mounjaro.

What is in the vial5

Tirzepatide, in a solution whose strength the pharmacy set. Where the approved products come as pens and vials at six fixed doses, a compounded preparation almost always comes as a multi-dose vial you draw from with a syringe — so the same milligram dose is a different mark on the syringe from one pharmacy to the next. That is the single most practical difference, and it has its own page.

Beyond that, what is in the vial varies. Some sellers add a vitamin or amino acid — B12, B6 or glycine — which no approved tirzepatide product contains; see what an add-in changes. And a compounded vial carries a beyond-use date rather than an expiry date, which is covered in storage and beyond-use dating.

Who is allowed to make it4

Two kinds of maker exist in federal law. A 503A pharmacy is a state-licensed pharmacy compounding for a named patient against that patient’s prescription. A 503B outsourcing facility is registered with FDA and can make larger batches.

From December 2022 tirzepatide was on FDA’s drug shortage list, and a shortage is what allowed broad compounding of it. FDA determined the shortage resolved in December 2024 and set deadlines for compounders to stop, and by March 2025 both routes had closed — FDA confirmed the 503A off-ramp shut on 10 March, and the 503B off-ramp shut on 19 March. Since then an outsourcing facility has had no route to bulk tirzepatide at all, and a 503A pharmacy may not regularly make what the law calls essentially a copy of the approved product unless a prescriber documents that the patient needs something significantly different.

The dated record, with every primary document linked, is on is compounded tirzepatide still legal?

What FDA has seen3

FDA publishes a running count. As of 31 May 2026 it had received more than 730 reports of adverse events associated with compounded tirzepatide. A report is not proof that the drug caused the event, but the pattern FDA describes is specific: reports that may be related to patients prescribed compounded semaglutide or tirzepatide

in doses beyond what is in the FDA-approved drug label. This could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule).

In other words, much of the risk FDA points to is in the dosing, not only in the vial — which is why the approved dosage chart is worth knowing even though a compounded vial has no label of its own.

How to read what you are buying

  • The pharmacy’s name and license. A compounded vial is made by a named pharmacy, and a seller should tell you which. Four checks, ten minutes.
  • The concentration, in milligrams per milliliter. Without it you cannot measure a dose.
  • The beyond-use date, and anything added. Both belong to the pharmacy, and both should be on or with the label.
  • Any FDA warning letter. Every one this index has matched is published in full on the trust page.

And whether it works is a separate question from what it is — the evidence, and its limits, are in does compounded tirzepatide work?

Questions

What is compounded tirzepatide?
Tirzepatide prepared by a pharmacy rather than manufactured and sold as an approved product. It contains the same active molecule as Zepbound and Mounjaro, but it is not FDA-approved, has no label of its own and is not a generic.
Is compounded tirzepatide FDA-approved?
No. FDA states that compounded drugs are not FDA-approved, which means it does not verify their safety, effectiveness or quality before they are marketed. The only FDA-approved tirzepatide products are Zepbound and Mounjaro.
Is compounded tirzepatide a generic?
No. There is no generic tirzepatide. A generic is approved by FDA as equivalent to the brand; a compounded preparation is not approved at all.
Who makes compounded tirzepatide?
A compounding pharmacy. Since FDA declared the shortage over, outsourcing facilities (503B) have had no route to bulk tirzepatide, and state-licensed pharmacies (503A) may not regularly make essentially a copy of the approved product unless a prescriber documents a significant difference for the patient.
What does compounded mean on a prescription?
That a pharmacist prepared the medicine by combining, mixing or altering ingredients for an individual patient, rather than dispensing a manufactured, FDA-approved product.

Sources

  1. FDA, Human Drug Compounding, content current as of 06/15/2026 FDA
  2. FDA, Compounding and the FDA: Questions and Answers, content current as of 09/16/2025 FDA
  3. FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss', content current as of 09/01/2026 FDA
  4. This site's legal-status page, which links the FDA orders, Federal Register entries and court dockets behind each date Read it
  5. DailyMed SPL records for MOUNJARO and ZEPBOUND (tirzepatide), both Eli Lilly and Company, revision 8/2026 DailyMed